Gossamer Bio, Inc. (GOSS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$9.95+7.22%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put GOSS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Stabilize or grow revenue: Comparison needs review.
View ThesisManagement screens weak on capital allocation, the balance sheet.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 97% in its worst 12-month stretch.
View RiskGossamer Bio's PAH drug pipeline must clear FDA hurdles to justify the price. Revenue fell 19.7% year over year in the last reported quarter. The stock trades at 61 times sales versus an 8.8 times peer median. The market is pricing in more growth than our forecast suggests. Our model puts the next-quarter miss probability near 67%. The primary revenue pillar is under pressure, though the comparison needs review. The thesis comparison is not yet verified. Peer multiples imply a price about 356% below where it trades. The thesis is on watch. This read is provisional.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Trailing returns as of 2026-11-04. GOSS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering GOSS (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare GOSS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GOSS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 2 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put GOSS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Submit NDA for seralutinib in PAH
NDA submission is a key regulatory milestone for seralutinib.
Advances: Submit NDA for seralutinib in PAH
FDA filing confirms progress towards NDA submission for seralutinib.
Threatens: Manage capital allocation with new convertible notes
Financing structure raises concerns about capital allocation.
Advances: Submit NDA for seralutinib in PAH
Funding supports NDA submission for seralutinib.
Threatens: Advance clinical development of seralutinib
Analysts' split on seralutinib impacts clinical development outlook.
Advances: Focus on revenue growth from collaboration with Chiesi
Earnings beat indicates strong revenue growth potential.
Revenue beat indicates positive growth trajectory.
Earnings call confirms revenue growth performance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.